Fig. 6

Siglec-15⁺ tumor cells or TAMs reversed CD8⁺ T cells prognosis value, and enhanced the prognosis value of Tregs and TAMs. A Kaplan–Meier survival analysis showed that CD8⁺ T cells localized to S15⁻ tumor cells had no prognostic significance (P = 0.162). B CD8⁺ T cells localized to S15⁺ tumor cells had an adverse effect on prognosis (P = 0.008). C CD8⁺ T cells predominantly localized to S15⁻ TAMs demonstrated a favorable effect on prognosis (P = 0.038). D CD8⁺ T cells predominantly localized to S15⁺ TAMs tend to have an adverse effect on prognosis (P = 0.057). E CD4⁺FoxP3⁺ Tregs surrounding S15⁻ tumor cells were associated with a bad prognosis (P = 0.035). F CD4⁺FoxP3⁺ Tregs surrounding S15⁺ tumor cells were correlated with poor outcome (P = 0.008). G CD4⁺FoxP3⁺ Tregs predominantly localized to S15⁻ TAMs had no effect on patient's survival (P = 0.117). H CD4⁺FoxP3⁺ Tregs predominantly localized to S15⁺ TAMs had an adverse effect on prognosis (P = 0.026). I CD68⁺ TAMs surrounding S15⁻ tumor cells had no significant effect on the prognosis (P = 0.088). J CD68⁺ TAMs predominantly localized to S15⁺ tumor cells demonstrated an adverse effect on prognosis (P = 0.026). K Univariate Cox regression analysis demonstrated that Siglec-15 do work as a risk factor associated with the prognosis of these immune cells